Update of the M. D. Anderson Cancer Center experience with hyper-CVAD and rituximab for the treatment of mantle cell and Burkitt-type lymphomas.

Luis Fayad, Deborah Thomas, Jorge Romaguera

Research output: Contribution to journal › Article › peer-review

44 Scopus citations

Fingerprint

Dive into the research topics of 'Update of the M. D. Anderson Cancer Center experience with hyper-CVAD and rituximab for the treatment of mantle cell and Burkitt-type lymphomas.'. Together they form a unique fingerprint.

Medicine & Life Sciences